IVFhMG 150iu (Menotrophin [HMG])

Product Overview

IVFhMG 150iu (Menotrophin [HMG]) is a recombinant human menotrophin preparation used primarily in assisted reproductive technology and endocrine therapy. Manufactured by Neova Biogene Private Limited, the product is supplied as a lyophilized powder for reconstitution with sterile water for injection. Each vial contains 150 international units of menotrophin, intended for a single administration. The medication is indicated for female infertility, male hypogonadism, and related infertility conditions, offering a targeted approach to stimulate gonadal function.

What is IVFhMG 150iu (Menotrophin [HMG])?

IVFhMG belongs to the class of gonadotropin‑releasing agents that mimic the action of endogenous luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). The active ingredient, menotrophin, is derived from genetically engineered Escherichia coli and is purified to pharmaceutical standards. Its molecular composition supports the development of ovarian follicles in women and testosterone production in men, making it a versatile tool in reproductive endocrinology. For detailed scientific background, refer to the PubMed database.

Uses and Benefits

Clinically, IVFhMG is employed to induce ovulation in women with polycystic ovary syndrome (PCOS) or anovulation, and to augment spermatogenesis in men with hypogonadotropic hypogonadism. Benefits include improved follicular recruitment, increased pregnancy rates in IVF cycles, and enhanced testosterone levels in male patients with documented deficiency. The drug’s consistent potency and reliable pharmacokinetics have contributed to its adoption in fertility clinics worldwide. Additional information on fertility treatments can be found at the Medical News Today resource.

How It Works

The mechanism of action involves binding to LH/FSH receptors on ovarian granulosa cells and Leydig cells in the testis. This interaction triggers intracellular cyclic AMP production, leading to steroidogenesis and follicular maturation. In women, the resulting estrogen surge promotes ovulation, while in men it stimulates Leydig cells to synthesize testosterone, supporting secondary sexual characteristics and sperm development. The recombinant formulation ensures a uniform biological activity comparable to native pituitary‑derived gonadotropins. For an in‑depth review of gonadotropin physiology, see the World Health Organization publications.

Dosage Guidelines

Administration of IVFhMG must be prescribed by a qualified reproductive endocrinologist or endocrinologist. The standard regimen for ovulation induction typically involves a single 150 IU intramuscular injection, followed by monitoring of follicular growth via ultrasound. In male hypogonadism, dosing may be adjusted based on serum testosterone levels and response to therapy. Patients should never self‑administer without medical supervision, and dosage modifications should only be performed under professional guidance. Detailed prescribing information is available on the U.S. Food and Drug Administration website.

Side Effects

Like all biologics, IVFhMG can cause adverse reactions. Common side effects include mild injection‑site pain, headache, and transient abdominal discomfort. Less frequently, patients may experience ovarian hyperstimulation syndrome (OHSS) in women or acne and mood changes in men. Severe allergic responses are rare but require immediate medical attention. Reporting of side effects to a healthcare provider ensures proper management and contributes to post‑marketing surveillance. For comprehensive safety data, consult the Drugs.com database.

Warnings and Precautions

IVFhMG is contraindicated in individuals with known hypersensitivity to any component of the formulation. Caution is advised in patients with a history of hormone‑sensitive cancers, thromboembolic disorders, or uncontrolled thyroid disease. Pregnant or breastfeeding women should not use this medication. Prior to initiation, a thorough clinical evaluation, including baseline hormone panels and imaging when indicated, is recommended. Healthcare professionals should discuss the risks and benefits with patients, particularly when treating underlying conditions such as diabetes or cardiovascular disease. Additional guidance on safe prescribing practices can be found on the MedlinePlus site.

Frequently Asked Questions

Q: What is the primary indication of IVFhMG 150iu? A: IVFhMG 150iu is indicated for the treatment of female infertility associated with ovulatory disorders, male hypogonadism, and related infertility conditions.

Q: How should the medication be stored? A: The lyophilized powder should be stored at 2‑8°C (refrigerated) and protected from light. Once reconstituted, the solution can be kept at room temperature for up to 24 hours.

Q: Can IVFhMG be used in combination with other fertility drugs? A: Yes, it is often used alongside recombinant FSH or human chorionic gonadotropin (hCG) under medical supervision to optimize follicular development.

Q: Is the product suitable for pediatric patients? A: Use in pediatric populations is not established; clinical studies have primarily involved adult patients with diagnosed infertility conditions.

Q: Where can I find the official prescribing information? A: The full prescribing details are published on the FDA Drugs portal and can also be accessed through the manufacturer’s website.

Related Products

• Emepitant (Aprepitant)
• Menotropin HMG 150iu Injection (Generic)
• Menotropin HMG 75iu Injection (Generic)
• IVFhMG 75iu (Menotrophin [HMG])
• hMG 1200iu Injection (Menotrophin)
• hMG 150iu Injection (Menotrophin)
• hMG 75iu Injection (Menotrophin)
• ZyHMG 75iu Injection (Menotrophin [HMG])
• ZyHMG 150iu Injection (Menotrophin (HMG))
• IVFhCG 5000 (HCG (Human Chorionic Gonadotropin))
• IVFhCG 1500iu (HCG (Human Chorionic Gonadotropin))
• Human Chorionic Gonadotropin 1500iu (Generic)